Document:

Exhibit 10.66

 Exhibit 10.66 

 

 

 LETTER OF UNDERSTANDING 

August 1, 2010 
 Douglas S.
Ingram 
 Executive Vice President, 

Chief Administrative Officer and Secretary 

Allergan, Inc. 
 2525 Dupont Drive

 Irvine, California 92612 

Dear Mr. Ingram: 
 You have
agreed to leave your current position as Executive Vice President, Chief Administrative Officer and Secretary (collectively “CAO”) and accept an expatriate assignment as Executive Vice President and President, Europe, Africa, Middle
East (“EAME”). 
 This letter agreement confirms the mutual understanding between you and Allergan of the terms and
conditions relating to your international assignment. If the terms set forth in this letter agreement are acceptable to you, please sign and return the attached copy to Corporate International Compensation. 

The term of your international assignment shall commence on or about August 1, 2010 and shall end on a date to be mutually agreed upon between
you and Allergan; provided, however, that subject to the terms of this letter agreement, Allergan may terminate your international assignment at any time and repatriate you to your Assignment Point of Origin or other location as
mutually agreed. 
  

	 	•	 	 Your Assignment Host Country:      UK 

  

	 	•	 	 Your Assignment Point of Origin (home country) is:          US 

 

	 	•	 	 Your Job Title will be:                      Executive
Vice President and President, EAME 

  

	 	•	 	 Performance Manager will be:         Mike Ball, President, Allergan 

To the extent there is any conflict between the terms of this letter agreement and any other written or oral agreement(s) relating to your
international assignment, this letter agreement will supersede such written or oral agreement(s). 
 In the event of any change in
circumstances or additional matters not presently known, Allergan reserves the right to make adjustments to the allowances and components of your international assignment with your written approval, which will not be unreasonably withheld or
delayed. Your international assignment allowances will be reviewed on an annual basis and will be adjusted accordingly based on changes to your base salary and family status. Except for additional benefits associated with an international assignment
and/or specific to working in your host region, the goal of this letter agreement is to ensure that in all material respects the 

 

 pg. 1 LOU 

 
compensation, benefits, perquisites and other rights attendant to your role as CAO are grandfathered and applicable for the duration of your international assignment. In the event that a
compensation, benefit, perquisite or other right attendant with your role as CAO has been overlooked in this letter agreement, it shall be added as a grandfathered feature as though originally included herein on the effective date of this letter
agreement. Attached hereto and made part of this letter agreement as Schedule A is an Assignment Component List that provides an overview of the features of your international assignment. 

 

	I.	 COMPENSATION OVERVIEW 

A. International Assignment Compensation and Benefits 

International assignment compensation consists of base salary, incentive compensation or bonuses, if applicable, and international
assignment-related allowances and benefits as detailed throughout this letter agreement. Your international assignment compensation will be based on a compensation philosophy known as the “Balance Sheet Compensation Approach.” The purpose
of the Balance Sheet Compensation Approach is to minimize economic gains and losses incurred by Allergan international assignees on a global assignment. 

1. Base Salary and Job Grade 
 Your base
salary will initially remain USD 550,800 per year and your job grade will be grandfathered at 15E. You will also be grandfathered for grade 15E EVP level compensation and benefits. You will be paid via home country payroll through your normal
salary account. Allergan will conduct salary reviews and performance evaluations in accordance with Allergan’s policies. The benchmark compensation data to be used for your annual salary review will be that for the CAO role. 

2. Cash Bonus and Incentive Compensation 

You will continue to be eligible to participate in Allergan’s short and long-term incentive, commission or variable compensation plans.

 During your assignment, changes to any component of your variable compensation, including the intent to sell stock, must be discussed
with Allergan to determine the most tax-efficient method of sale. 
  

	 	•	 	 Your bonus target will be: 72% of base salary. 

  

	 	•	 	 Your long-term incentive target will be at the 75th percentile for the CAO position, unless Allergan’s compensation philosophy regarding long-term
incentive targets, as disclosed in Allergan’s annual proxy statement, is modified, in which case your long-term incentive target will be consistent with that new disclosed target. 

3. US Executive Perquisites 
 You will continue to be
eligible for US executive perquisites as set forth below. 
  

	 	•	 	 Tax and Financial Planning Services Fees:          USD 10,000 

 

	 	•	 	 Annual Miscellaneous Allowance:          USD 10,000 

 

 pg. 2 LOU 

 4. Stock Ownership 

You will continue to have a stock ownership requirement of three (3) times your annual base salary. In the event the stock ownership
requirement for Grade 15E EVPs is modified, you will be required to comply with such modified stock ownership requirement. 
 5. Change in Control 

 Attached as Schedule B is your executed Change in Control Agreement, which, unless otherwise modified for all other grade 15E
level employees, will remain in effect for the duration of your international assignment. 
 6. Benefits 

To the maximum extent practicable and subject to the terms and conditions of Allergan’s applicable plans and laws, you will continue to be
covered by home country benefit and retirement programs, including social security. In cases where this is not possible, every reasonable effort will be made to provide suitable alternative coverage (i.e., alternative medical coverage for employees
from countries where medical coverage cannot be extended to another jurisdiction). Further information can be found in the Home Country Benefits and International Benefit Plan Guides. 

While on your international assignment, your benefits plans are as follows: 

 

	 	•	 	 Medical, Dental, Vision:     AETNA 

  

	 	•	 	 Life Insurance and AD&D: AETNA 

  

	 	•	 	 Executive Life Insurance:   USD 1,500,000 

  

	 	•	 	 Sick Leave and LTD:         Current US benefits plan 

 

	 	•	 	 Retirement Plan:                Allergan Inc. Pension Plan & Supplemental
Executive Retirement Plan 

  

	 	•	 	 Business Travel Accident Insurance 

  

	 	•	 	 International SOS Plan 

 7. Vacations

 While on your international assignment, you will maintain your accrued, unused vacation and will remain eligible for vacation
accrual based on your home country schedule. Vacation, travel allowances, and other international policies and procedures of Allergan will apply to you and those dependents that will reside in the host country. 

8. Holidays/Work Schedule 
 You will follow
the hours, workdays and public holidays observed in your host country even if they are substantially different from those observed in your home country. 
  

	II.	 ASSIGNMENT ALLOWANCES and BENEFITS 

A. Pre-Departure and Relocation 

The following section details the relocation allowances and benefits Allergan will provide to you and your family during pre-departure and upon
initial relocation to the assignment location. 
  

 pg. 3 LOU 

 1. Immigration Assistance – Foreign Visas/Work Permits 

Your international assignment will be subject to your obtaining and maintaining any necessary business entry and work visas (including successful
completion of any medical examination that may be required to obtain a work permit or visa in the countries to which you will be traveling during the assignment). Non-compliance with immigration laws may result in a legal detriment to employees,
Allergan and potentially our customers. International assignees are expected to comply with all laws and regulations of each foreign location where they may visit or work, including health and safety requirements. Any violation of foreign
immigration laws and regulations of the host country or of the laws of any other country may subject an assignee to disciplinary action, which may include dismissal. You are not permitted to move to the host country and begin your international
assignment until you have obtained all necessary immigration documentation. 
 Allergan’s Corporate International Compensation
team will coordinate with the appropriate immigration attorney to obtain the necessary documentation for the assignment to occur (i.e., passports, visa, work permits, etc.). Allergan will pay for these and other costs incurred in obtaining permits
for you to work in the host country and for your dependents to accompany you. You should ensure timely provision of all required information for you and your accompanying family members to enable the application process to happen in the most timely
and efficient manner as possible. 
 2. Tax Consultations 

You are required to meet with Allergan’s designated tax services provider for an initial review of Allergan’s tax policies and practices
both prior to departure in the home country and upon arrival in the host country. Allergan’s Corporate International Compensation team will arrange these consultations for you with Allergan’s designated tax services provider. 

3. Will Preparation and Estate Planning 
 As
the laws governing the disposition and taxation of estates are different in every country and possibly in localities within a country, Allergan recommends that the assignee either prepare a new will and/or trust or have an existing will reviewed
before the start of the international assignment. 
 4. Cross-Cultural Training 

To assist you and your family with the adjustment to your host country, Allergan will provide cross-cultural training through Allergan’s
designated service provider. 
 5. Transportation of Household Goods and Personal Effects 

Allergan will pay the customary charges of shipping your required household goods, furnishings and personal effects for you and accompanying family
up to the applicable limits. 
 Surface shipments are provided when going into unfurnished housing. At the time of repatriation, or
transfer to another country, you will be allowed to transport a surface shipment of up to 110% of the weight of the original shipment at Allergan’s cost. Charges for transportation of household goods in excess of this weight will be your
personal responsibility. 
 Air shipments to complement surface shipments are provided. At the time of repatriation, or transfer to
another country, you will be allowed to transport an air shipment of up to 110% of the 
  

 pg. 4 LOU 

 
weight of the original shipment at Allergan’s cost. Charges for transportation of household goods in excess of this weight will be your personal responsibility. 

6. Domestic Pets 
 Only if applicable,
Allergan will reimburse costs associated with the shipment of two domestic household pets to the host country up to a maximum of the equivalent of $10,000 USD. However, you are responsible for obtaining and paying for documents, inoculations, and
kenneling costs to permit the shipment of pets from one location to another. 
 7. Home Country Residence 

The decision to rent or sell your primary residence in the home country is your personal decision. However, Allergan encourages you to consider
your options regarding maintaining or selling the home country residence. 
 Should you elect to sell your home, it will be at your
expense and you are responsible for any and all home sale/return purchase expenses, and the risk/payment of any future gain-on-sale tax liability or an exchange rate gain related to the sale of your home. 

8. Household Goods Storage 
 For the
duration of your international assignment, Allergan will pay the cost of temporarily warehousing your household goods items left in the home country, including up to 2 automobiles. 

9. Home Country Automobiles 
 You will be
reimbursed for the loss sustained in the “forced sale” or penalties for automobile lease breakage of up to one personal automobile if single, and two personal automobiles if married/civil partnership status. Reimbursement for loss-on-sale
will be limited to the difference between the actual sale price and the average retail selling price of the automobiles (e.g. Kelley Blue Book value in the U.S.). However, the maximum amount is limited to $5,000 USD per automobile for loss-on-sale
or penalties for lease breakage. 
 Should you dispose of your automobile in advance of the departure date, Allergan will reimburse car
rental expenses, excluding fuel, tolls, parking etc., of up to a maximum of two weeks. 
 10. Relocation Allowance 

You will receive a one-time, non-accountable payment of one month’s base salary to cover miscellaneous expenses associated with your
relocation to your host country. 
  

	 	•	 	 Your Relocation Allowance is: USD 45,900 

11. Travel Arrangements 
 You and your
accompanying family are provided with travel to the home country and compensated for business-class airfare for your family. Your travel will be will consistent with the policy in effect for the CAO position. You are responsible for any indirect
routing costs. 
 12. Temporary Living 

Allergan will cover actual lodging up to a maximum of 45 days while your household goods are being packed and prepared for shipment in the home
country as well as in the host country until suitable “permanent” housing can be located. In addition, you will receive a per diem and be 

 

 pg. 5 LOU 

 
reimbursed for automobile rental expenses, if necessary, during the period of temporary living. Reimbursement excludes fuel, tolls and parking. 

 

	 	•	 	 Your Per Diem is: GBP 40 per person 

Allergan will also cover the cost of a one-bedroom accommodation for you after your family has relocated to the host country and while you remain
in the home country. 
 13. Destination Services 

To assist in settling into the new environment, you and your family are entitled to services provided by a Company-designated
relocation/destination services provider in the host country. 
 14. Spousal/Domestic Partner Assistance 

If your spouse/civil partner is relocating on the international assignment with you, he or she will receive a one-time non-accountable payment of
USD 3,000. 
 B. Assignment Benefits 

The following section details the various benefits Allergan provides to you and your relocating family members throughout the international
assignment duration. 
 1. Cost of Living Adjustment 

While on your international assignment, you may incur living costs different from those in your home country. Allergan intends to ensure that you
will not experience unusual losses as a result of the assignment. If living costs are higher in your host country than in your home country, your compensation package will include a monthly cost of living allowance to offset these cost differences.

 A Cost-of-Living Allowance (COLA) will be paid to you based on your living circumstances. The COLA is based on the international
assignment data service provider index and will be reviewed and potentially adjusted once every four months in accordance with newly published indices and exchange rates. 

The cost of living allowance is effective from the start of your assignment and may be modified by Allergan during your assignment at its
discretion. 
  

	•	 	 Your COLA will be:          GBP 1,940 per month 

2. Host Country Housing 
 Allergan will pay
rent and utilities, including telephone and cable television installation, but excluding telephone call and monthly cable television plan expenses in your new location. The arrangements and lease amounts associated with your assignment will be
approved by your Assignment Manager. 
 Housing Lease: 

Where applicable and at Allergan’s discretion, the housing lease may be entered or executed in the name of Allergan or designated service
provider when it is tax advantageous. In this case, Allergan will typically pay rent directly to the landlord and you will be reimbursed separately for utilities if not included in the rental fees. In all cases, Allergan must approve leases prior
to commitment and signing. 
  

 pg. 6 LOU 

 Where possible, all leases should be negotiated in host country currency and a diplomatic clause for
purposes of breaking the lease should be included in the lease where practical. 
 Purchase of Housing in the Host Country: 

Allergan strongly advises against purchasing a personal residence in the host country. Purchase of host country housing generally restricts your
mobility and could result in a substantial financial loss should you be unable to dispose of the property at a reasonable sales price upon the completion or termination of the international assignment. No Allergan assistance will be provided on
either purchase or sale of host country property. 
 3. Host Country Auto Assistance 

Allergan will provide automobile assistance for you during your assignment to your host country based upon local country guidelines. 

 

	•	 	 Your Host Country Automobile Benefit or Allowance is: Per UK Automobile Policy 

4. Reimbursement of Schooling Costs for Children 

Allergan will reimburse the cost of international or private schooling. Tuition and related fees upon receipt of appropriate documentation will be
reimbursed for dependent children in the host country, subject to the following guidelines: 
  

	•	 	 Children must accompany you while on assignment; 

  

	•	 	 Children must be enrolled in the nearest school starting with nursery/pre-school (under structured educational programs), kindergarten, elementary and
secondary levels for each eligible child. The school must allow for normal grade promotion upon return to the home country; 

  

	•	 	 Expenses related to tuition, transportation to and from school, books, uniforms and related fees (e.g. application fees, etc.) will be reimbursed for each
eligible child; and 

  

	•	 	 Tuition costs for college or university level education as well as for boarding schools in the home, host or other foreign country will not be reimbursed.

 Dependent children under the age of 24 attending educational institutions outside of the host country on a full-time
basis and who are not accompanying the assignee and family will be entitled to visit their family at the host country once per year. Travel reimbursement will be provided by Allergan for the most direct air route by business class air. 

5. Driver Training 
 If needed, Allergan
will pay the cost of driver’s education for you and eligible dependants if the training is started within 45 days of arrival. 
 6. Home Leave

 While on your international assignment, you will be eligible for two round-trip home leave trips every twelve months from your
assignment start date for you and your accompanying family members for the most direct air route by coach class air, in the case of your family, and class of service applicable to the CAO position, in your case. Allergan will also reimburse rental
car expenses following reimbursement guidelines established under Allergan’s home country business travel policy. Time-off for home leave will be charged to your vacation accrual, except for

  

 pg. 7 LOU 

 
any business days in the office. 
 Home leaves must be taken in the year provided,
and may not be carried over to the next year. The purpose of home leave is to renew ties with family and friends, and work associates in the home country and to stay informed of economic, political, cultural and social trends. If you elect to take
your home leave trips and travel by indirect route (i.e. other stopovers or non-standard routing), you will be reimbursed for the actual transportation cost expense to and from the indirect locations up to the airfare cost that would be incurred if
travel had been by direct route to the established home base. Such special arrangements must be approved in advance by Corporate International Compensation. 

In lieu of you and your family traveling home, travel reimbursement for a visit by your and/or your spouse’s parents to the host country will
be provided twice every twelve months for the most direct air route by business class air. 
 Throughout your international assignment,
all expenses associated with standard, business-related travel will be reimbursed per applicable Allergan business travel policy. 
 7. Emergency
Provisions 
 Bereavement 
 If
it becomes necessary for you and/or dependants to return to your home country because of an emergency in your immediate family (e.g., death or serious injury) arising in your home country, round trip business-class airfare will be reimbursed.

 Your home country bereavement policy (or equivalent) should be referred to for the definition of “immediate family” and
“emergency,” and for any other benefits that may be applicable (such as paid or unpaid leave). 
 Medical 

In the event the assignee or his or her dependants suffer an injury or illness of such severity that in the assignee’s opinion, adequate
medical facilities are not available locally, the cost of transportation to the home country or another location where facilities are available will be paid by Allergan. 

Evacuation 
 Allergan will ensure provisions for emergency
evacuation through its designated third-party service providers. 
  

	III.	 END OF ASSIGNMENT 

A. Termination of Employment 

Subject to the terms of this letter agreement, your employment by Allergan remains at-will and you or Allergan are free to terminate such
employment at any time, for any reason, provided it is not an unlawful reason. 
 1. With Cause 

While on your international assignment, if your employment is terminated by Allergan with cause, Allergan will only pay for your return airfare for
you and your family to your point of origin in the home country and will return your household goods to your point of origin in the home 

 

 pg. 8 LOU 

 
country. You will not be entitled to any further benefits or allowances except as may be set forth in Allergan’s existing compensation or benefit plans, policies or agreements. 

2. Without Cause 
 While on your
international assignment, if your employment is terminated by Allergan without cause, in addition to any other benefits or compensation to which you may be entitled under Allergan’s currently existing policies, plans, or agreements (including,
without limitations those policies or agreements regarding change in control, severance and the like), Allergan will provide a repatriation tax consultation, pay for your return airfare for you and your family to your point of origin in the home
country, return your household goods to your point of origin in the home country, provide a relocation allowance and cover the costs of temporary living expenses. 

B. Resignation 

if you voluntarily resign your employment and there is a legal requirement for providing return transportation and removal of personal goods from
the host country, payment for shipment of household goods and travel for you and your family to the point of origin in the home country will be reimbursed by Allergan. To be eligible to receive the benefits outlined above, relocation to the home
country must within a period of 30 days after the effective date of termination. You will not receive any relocation or repatriation benefits if you fail to repatriate by the date established by Allergan. No cash-in-lieu payments will be made. All
salary and assignment allowance payments will cease as of the date of termination of employment. 
 In addition, other than those benefits
which may be required for reimbursement by Allergan under host country law, if you resign your employment within twelve months of beginning your international assignment, you will be required to repay Allergan a pro-rated amount of the
relocation-related expenses incurred by Allergan on your behalf. The amount will be based on the length of time you have spent abroad working on assignment (See Schedule C: Relocation Repayment Agreement). The Relocation Repayment Agreement
must be signed prior to beginning your international assignment. 
 You must also remit any unpaid tax equalization settlements due to
Allergan upon your termination. Company-sponsored foreign visas/work-permits will terminate on the earlier of the last day of employment or last day in the host country. If applicable, you must remit all Company-sponsored, foreign immigration
documentation to Allergan and may not use any such documents for other employment. 
 TAXES 

A. Tax Interview and Preparation 

Allergan will pay for the services of Allergan’s designated external tax services provider to meet with you to review the details of the
Allergan’s tax equalization policy and to prepare all required home and host country individual tax returns while you are on international assignment. Throughout your international assignment, you must use the tax services firm chosen by
Allergan for the preparation of all required individual tax returns. 
 B. Tax Equalization 

The purpose of tax equalization is to ensure that as a result of your international assignment, your

  

 pg. 9 LOU 

 
tax obligation is not added to significantly nor results in significant tax savings due to differences in income and social taxes between the home and host countries. It ensures that your
out-of-pocket obligations remain approximately the same as they would have had your remained at home. 
 During the assignment, Allergan
will reimburse all home and host country income taxes, including social security assessed during the international assignment. In return, you will be required to contribute a “hypothetical tax” (see below), which is approximately equal to
the amount of income and social security that you would have incurred in the home country had you not gone on assignment. 
 Once your
annual individual tax returns are finalized, a tax equalization calculation is prepared by Allergan’s designated tax services provider. Your final hypothetical tax obligation is compared with the amount you have paid (actual and hypothetical
taxes) during the applicable tax year. This comparison may result in a balance due to/from Allergan. The settlement of this balance represents the completion of the year’s tax equalization process. 

C. Hypothetical Tax Deduction 

There will be an amount per pay cycle deducted from your pay corresponding to the approximate home country income taxes you would have paid on
Allergan base salary had you remained in your home country (the “hypothetical tax”). Preliminary hypothetical taxes are projected for the year based on hypothetical stay-at-home income and applicable deductions. This hypothetical tax will
include home country income tax, state or province income tax and all social taxes. 
 To the extent that a bonus is received, it will be
taxed based on your effective tax rate on your hypothetical tax calculation. The preliminary hypothetical tax will be revised during the course of the year whenever there is a change in tax law, base salary, filing status, number of personal
exemptions, or any other material change in net personal income. 
 You hereby authorize Allergan to make any necessary hypothetical tax
deductions from your pay pursuant to Allergan’s tax equalization policy. 
 IV. MISCELLANEOUS 

A. Continuing Obligations 

In accepting this assignment, you agree that you will continue to abide by the terms of Allergan’s applicable confidentiality and employment
agreements, which remain in full force and effect. Further, you will refrain from local political activity or acceptance of bribes or gifts or other activities in violation of local law. 

B. Severability 

If any provision of this letter agreement is held by any court of competent jurisdiction to be invalid or unenforceable in whole or in part, the
remaining provisions of this letter agreement will continue in full force and effect. 
 C. Entire Agreement

 This letter agreement constitutes the entire agreement between you and Allergan regarding the terms of your international
assignment and is the complete, final, and exclusive embodiment of your agreement with regard to that subject matter, and supersedes any other promises, 

 

 pg. 10 LOU 

 
warranties, representations or agreement, whether written or oral. This letter agreement is entered into without reliance on any promise or representation other than those expressly contained
herein, and it cannot be modified except by written agreement executed by you and Allergan’s Corporate International Compensation group. 

D. Governing Law 

The laws of the State of California govern this letter agreement and your employment relationship with Allergan, without regard to its choice of
law rules. 
 E. Policy Administration 

While it is anticipated that the terms of this letter agreement will continue throughout your international assignment, Allergan reserves the right
to change the administration of any allowances and benefit programs provided herein. 
 Please sign and return one copy of this letter
agreement, as your acknowledgment of receipt and understanding of Allergan’s Tax Equalization Policy, as well as your acceptance and understanding of the conditions set forth in this letter agreement and its attachments. 

We are confident you will make a significant contribution to Allergan during the course of your international assignment and wish you much success.

  

	
	 Sincerely,

	
	 
	Kathy Burns
	Vice President, Compensation and Benefits

  

 pg. 11 LOU 

 SIGNED AND AGREED: 

Douglas S. Ingram:            /s/ Douglas S.
Ingram                                        
 
 Date:                August 1,
2010                                         
                    
 Allergan Employing
Entity:            Allergan, Inc. 

CC:                KPMG, Brookfield, Human Resources, Accounting 

After all signatures have been affixed, please return this agreement to: 

Allergan, Inc. 

Corporate International Compensation 

T2-1D 

2525 Dupont Drive 

Irvine, CA 92623-9534 
  

 pg. 12 LOUForm of Stock Option Agreement

 Exhibit 10.2 

UNITED STATES 

TESSERA TECHNOLOGIES, INC. 

2003 EQUITY INCENTIVE PLAN 

STOCK OPTION GRANT NOTICE AND 

STOCK OPTION AGREEMENT 

Tessera Technologies, Inc., a Delaware corporation (the “Company”), pursuant to its 2003 Equity Incentive Plan
(as amended to date, the “Plan”), hereby grants to the holder listed below (“Participant”), an option to purchase the number of shares of the Company’s common stock, par value $0.001
(“Stock”), set forth below (the “Option”). This Option is subject to all of the terms and conditions set forth herein and in the Stock Option Agreement attached hereto as Exhibit A (the
“Stock Option Agreement”) and the Plan, which are incorporated herein by reference. Unless otherwise defined herein, the terms defined in the Plan shall have the same defined meanings in this Grant Notice and the Stock Option
Agreement. 
  

			
	Participant:	 	
		
	Employee ID:	 	
		
	Grant Date:	 	
		
	Vesting Commencement Date:	 	
		
	Exercise Price per Share:	 	
		
	 Total Number of Shares

Subject to the Option:
	 	
		
	Total Exercise Price:	 	
		
	Expiration Date:	 	

  

			
	 Type of Option:
	  	 ̈ Incentive Stock Option     ̈ Nonstatutory Stock Option

		
	 Vesting Schedule:
	  	The Option shall vest and become exercisable according to the following indicated schedule:
		
		  	  ̈        The Option shall vest and
become exercisable with respect to twenty-five percent (25%) of the shares of Stock subject to the Option on the first anniversary of the Vesting Commencement Date, and thereafter the balance of the Option shall vest and become exercisable in a
series of thirty-six (36) successive equal monthly installments measured from the first anniversary of the Vesting Commencement Date, subject to Participant’s continued status as a Service Provider through each of such vesting dates, such
that the Option shall be fully vested and exercisable with respect to all of the shares of Stock subject to the Option as of the fourth anniversary of the Vesting Commencement Date.

		
		  	  ̈        The Option shall vest and
become exercisable in a series of forty-eight (48) successive equal monthly installments over the four-year period measured from the Vesting Commencement Date, subject to Participant’s continued status as a Service Provider through each of
the vesting dates, such that the Option shall be fully vested and exercisable with respect to all of the shares of Stock subject to the Option as of the fourth anniversary of the Vesting Commencement Date.

 By his or her signature, the Participant agrees to be bound by the terms and conditions of
the Plan, the Stock Option Agreement and this Grant Notice. The Participant has reviewed the Stock Option Agreement, the Plan and this Grant Notice in their entirety, has had an opportunity to obtain the advice of counsel prior to executing this
Grant Notice and fully understands all provisions of this Grant Notice, the Stock Option Agreement and the Plan. Participant hereby agrees to accept as binding, conclusive and final all decisions or interpretations of the Administrator upon any
questions arising under the Plan or relating to the Option. 
 I have read and accepted all terms and conditions of the Plan
posted on www.etrade.com. Below are instructions on how to access the Plan: 
 1. Log into your E*TRADE account.

 2. Click on Employee Stock Plan. 

3. Click on Company Info. 

4. Click on Documents. 

5. Click on 2003 Plan. 
  

									
	TESSERA TECHNOLOGIES, INC.	 		 	PARTICIPANT
					
	 By:
	 	  
	 		 	By:	 	  

	 Print Name:
	 	 Michael Anthofer
	 		 	Print Name:	 	  

	 Title:
	 	 EVP, Chief Financial Officer
	 		 	Date:	 	  

	 Address:
	 	 3025 Orchard Parkway
	 		 		 	
		 	 San Jose, CA 95134
	 		 		 	
	 Date:
	 	  
	 		 		 	

 EXHIBIT A 

TO STOCK OPTION GRANT NOTICE 

STOCK OPTION AGREEMENT 

Pursuant to the Stock Option Grant Notice (the “Grant Notice”) to which this Stock Option Agreement (this
“Agreement”) is attached, Tessera Technologies, Inc., a Delaware corporation (the “Company”), has granted to the Participant an option under the Company’s 2003 Equity Incentive Plan (as amended to
date, the “Plan”) to purchase the number of shares of Stock indicated in the Grant Notice. 
 ARTICLE
I. 
 GENERAL 

1.1 Defined Terms. Wherever the following terms are used in this Agreement they shall have the meanings specified below, unless
the context clearly indicates otherwise. Capitalized terms not specifically defined herein shall have the meanings specified in the Plan and the Grant Notice. 

(a) “Termination of Consultancy” shall mean the time when the engagement of the Participant as a Consultant to
the Company or a Parent or Subsidiary is terminated for any reason, with or without cause, including, but not by way of limitation, by resignation, discharge, death or retirement, but excluding: (i) terminations where there is a simultaneous
employment or continuing employment of the Participant by the Company or any Parent or Subsidiary, and (ii) terminations where there is a simultaneous re-establishment of a consulting relationship or continuing consulting relationship between
the Participant and the Company or any Parent or Subsidiary. The Administrator, in its absolute discretion, shall determine the effect of all matters and questions relating to Termination of Consultancy, including, but not by way of limitation, the
question of whether a particular leave of absence constitutes a Termination of Consultancy. Notwithstanding any other provision of the Plan, the Company or any Parent or Subsidiary has an absolute and unrestricted right to terminate a
Consultant’s service at any time for any reason whatsoever, with or without cause, except to the extent expressly provided otherwise in writing. 

(b) “Termination of Directorship” shall mean the time when the Participant, if he or she is or becomes a
Non-Employee Director, ceases to be a Director for any reason, including, but not by way of limitation, a termination by resignation, failure to be elected, death or retirement. The Board, in its sole and absolute discretion, shall determine the
effect of all matters and questions relating to Termination of Directorship with respect to Non-Employee Directors. 
 (c)
“Termination of Employment” shall mean the time when the employee-employer relationship between the Participant and the Company or any Parent or Subsidiary is terminated for any reason, with or without cause, including, but
not by way of limitation, a termination by resignation, discharge, death, disability or retirement; but excluding: (i) terminations where there is a simultaneous reemployment or continuing employment of the Participant by the Company or any
Parent or Subsidiary, and (ii) terminations where there is a simultaneous establishment of a consulting relationship or continuing consulting relationship between the Participant and the Company or any Subsidiary. The Administrator, in its
absolute discretion, shall determine the effect of all matters and questions relating to Termination of Employment, including, but not by way of limitation, the question of whether a particular leave of absence constitutes a Termination of
Employment. 

 (d) “Termination of Services” shall mean the last to occur of
Participant’s Termination of Consultancy, Termination of Directorship or Termination of Employment, as applicable. 
 1.2
Incorporation of Terms of Plan. The Option is subject to the terms and conditions of the Plan which are incorporated herein by reference. In the event of any inconsistency between the Plan and this Agreement, the terms of the Plan shall
control. 
 ARTICLE II. 

GRANT OF OPTION 

2.1 Grant of Option. In consideration of the Participant’s past and/or continued employment with or service to the Company or
a Subsidiary and for other good and valuable consideration, effective as of the Grant Date set forth in the Grant Notice (the “Grant Date”), the Company irrevocably grants to the Participant the Option to purchase any part or
all of an aggregate of the number of shares of Stock set forth in the Grant Notice, upon the terms and conditions set forth in the Plan and this Agreement. Unless designated as a Nonstatutory Stock Option in the Grant Notice, the Option shall be an
Incentive Stock Option to the maximum extent permitted by law. 
 2.2 Exercise Price. The exercise price of the shares of
Stock subject to the Option shall be as set forth in the Grant Notice, without commission or other charge; provided, however, that the price per share of the shares of Stock subject to the Option shall not be less than 100% of the Fair
Market Value of a share of Stock on the Grant Date. Notwithstanding the foregoing, if this Option is designated as an Incentive Stock Option and the Participant owns (within the meaning of Section 424(d) of the Code) more than 10% of the total
combined voting power of all classes of stock of the Company or any “subsidiary corporation” of the Company or any “parent corporation” of the Company (each within the meaning of Section 424 of the Code), the price per share
of the shares of Stock subject to the Option shall not be less than 110% of the Fair Market Value of a share of Stock on the Grant Date. 

2.3 Consideration to the Company. In consideration of the grant of the Option by the Company, the Participant agrees to render
faithful and efficient services to the Company or any Parent or Subsidiary. Nothing in the Plan or this Agreement shall confer upon the Participant any right to continue in the employ or service of the Company or any Parent or Subsidiary or shall
interfere with or restrict in any way the rights of the Company and its Parents and Subsidiaries, which rights are hereby expressly reserved, to discharge or terminate the services of the Participant at any time for any reason whatsoever, with or
without cause, except to the extent expressly provided otherwise in a written agreement between the Company or a Parent or Subsidiary and the Participant. 

ARTICLE III. 

PERIOD OF EXERCISABILITY 

3.1 Commencement of Exercisability. 

(a) Subject to Sections 3.2, 3.3, 5.8 and 5.10 hereof, the Option shall become vested and exercisable in such amounts and at such times
as are set forth in the Grant Notice. 
 (b) No portion of the Option which has not become vested and exercisable at the date of
the Participant’s Termination of Services shall thereafter become vested and exercisable, except as may be otherwise provided by the Administrator or as set forth in a written agreement between the Company and the Participant. 

 (c) Notwithstanding anything in this Sections 3.1 hereof, pursuant to Section 13(d) of
the Plan, the Option shall become fully vested and exercisable in the event of a Change in Control, in connection with which the successor corporation does not assume the Option or substitute an equivalent right for the Option. Should the successor
corporation assume the Option or substitute an equivalent right, then no such acceleration shall apply. 
 3.2 Duration of
Exercisability. The installments provided for in the vesting schedule set forth in the Grant Notice are cumulative. Each such installment which becomes vested and exercisable pursuant to the vesting schedule set forth in the Grant Notice shall
remain vested and exercisable until it becomes unexercisable under Section 3.3 hereof. 
 3.3 Expiration of Option.
The Option may not be exercised to any extent by anyone after the first to occur of the following events: 
 (a) The expiration
of ten years from the Grant Date; 
 (b) If this Option is designated as an Incentive Stock Option and the Participant owned
(within the meaning of Section 424(d) of the Code), at the time the Option was granted, more than 10% of the total combined voting power of all classes of stock of the Company or any “subsidiary corporation” of the Company or any
“parent corporation” of the Company (each within the meaning of Section 424 of the Code), the expiration of five years from the Grant Date; 

(c) The expiration of three months from the date of the Participant’s Termination of Services, unless such termination occurs by
reason of the Participant’s death or Disability; or 
 (d) The expiration of one year from the date of the
Participant’s Termination of Services by reason of the Participant’s death or Disability. 
 The Participant
acknowledges that an Incentive Stock Option exercised more that three months after the Participant’s Termination of Employment, other than by reason of death or Disability, will be taxed as a Nonstatutory Stock Option. 

3.4 Special Tax Consequences. The Participant acknowledges that, to the extent that the aggregate Fair Market Value (determined as
of the time the Option is granted) of all shares of Stock with respect to which Incentive Stock Options, including the Option, are exercisable for the first time by the Participant in any calendar year exceeds $100,000, the Option and such other
options shall be Nonstatutory Stock Options to the extent necessary to comply with the limitations imposed by Section 422(d) of the Code. The Participant further acknowledges that the rule set forth in the preceding sentence shall be applied by
taking the Option and other “incentive stock options” into account in the order in which they were granted, as determined under Section 422(d) of the Code and the Treasury Regulations thereunder. 

ARTICLE IV. 

EXERCISE OF OPTION 

4.1 Person Eligible to Exercise. Except as provided in Sections 5.2(b), during the lifetime of the Participant, only the
Participant may exercise the Option or any portion thereof. After the death of the 

 
Participant, any exercisable portion of the Option may, prior to the time when the Option becomes unexercisable under Section 3.3 hereof, be exercised by the Participant’s personal
representative or by any person empowered to do so under the deceased the Participant’s will or under the then applicable laws of descent and distribution. 

4.2 Partial Exercise. Any exercisable portion of the Option or the entire Option, if then wholly exercisable, may be exercised in
whole or in part at any time prior to the time when the Option or portion thereof becomes unexercisable under Section 3.3 hereof. 

4.3 Manner of Exercise. The Option, or any exercisable portion thereof, may be exercised solely by delivery to the Secretary of
the Company (or any third party administrator or other person or entity designated by the Company) of all of the following prior to the time when the Option or such portion thereof becomes unexercisable under Section 3.3 hereof: 

(a) An Exercise Notice in a form specified by the Administrator, stating that the Option or portion thereof is thereby exercised, such
notice complying with all applicable rules established by the Administrator; 
 (b) The receipt by the Company of full payment
for the shares of Stock with respect to which the Option or portion thereof is exercised, including payment of any applicable withholding tax, which may be in one or more of the forms of consideration permitted under Section 4.4 hereof or by
the Plan; 
 (c) Any other written representations as may be required in the Administrator’s reasonable discretion to
evidence compliance with the Securities Act or any other applicable law rule, or regulation; and 
 (d) In the event the Option
or portion thereof shall be exercised pursuant to Section 4.1 hereof by any person or persons other than the Participant, appropriate proof of the right of such person or persons to exercise the Option. 

Notwithstanding any of the foregoing, the Company shall have the right to specify all conditions of the manner of exercise, which conditions may vary by
country and which may be subject to change from time to time. 
 4.4 Method of Payment. Payment of the exercise price
shall be by any of the following, or a combination thereof, at the election of the Participant: 
 (a) Cash; 

(b) Check; 

(c) Delivery of a notice that the Participant has placed a market sell order with a broker with respect to shares of Stock then issuable
upon exercise of the Option, and that the broker has been directed to pay a sufficient portion of the net proceeds of the sale to the Company in satisfaction of the aggregate exercise price; provided, that payment of such proceeds is then
made to the Company upon settlement of such sale; 
 (d) With the consent of the Administrator, surrender of other shares of
Stock which (A) in the case of shares of Stock acquired from the Company, have been owned by the Participant for more than six (6) months on the date of surrender (or such other period of time as the Administrator may determine), and
(B) have a Fair Market Value on the date of surrender equal to the aggregate exercise price of the shares of Stock with respect to which the Option or portion thereof is being exercised; 

 (e) With the consent of the Administrator, surrendered shares of Stock issuable upon the
exercise of the Option having a Fair Market Value on the date of exercise equal to the aggregate exercise price of the shares of Stock with respect to which the Option or portion thereof is being exercised; or 

(f) With the consent of the Administrator, property of any kind which constitutes good and valuable consideration. 

4.5 Conditions to Issuance of Stock Certificates. The shares of Stock deliverable upon the exercise of the Option, or any portion
thereof, may be either previously authorized but unissued shares of Stock or issued shares of Stock which have then been reacquired by the Company. Such shares of Stock shall be fully paid and nonassessable. The Company shall not be required to
issue or deliver any shares of Stock purchased upon the exercise of the Option or portion thereof prior to fulfillment of all of the following conditions: 

(a) The admission of such shares of Stock to listing on all stock exchanges on which such Stock is then listed; 

(b) The completion of any registration or other qualification of such shares of Stock under any state or federal law or under rulings or
regulations of the Securities and Exchange Commission or of any other governmental regulatory body, which the Administrator shall, in its absolute discretion, deem necessary or advisable; 

(c) The obtaining of any approval or other clearance from any state or federal governmental agency which the Administrator shall, in its
absolute discretion, determine to be necessary or advisable; 
 (d) The receipt by the Company of full payment for such shares
of Stock, including payment of any applicable withholding tax, which may be in one or more of the forms of consideration permitted under Section 4.4 hereof or by the Plan; and 

(e) The lapse of such reasonable period of time following the exercise of the Option as the Administrator may from time to time establish
for reasons of administrative convenience. 
 (f) Shares of Stock issued upon exercise of the Option shall be issued to
Participant or Participant’s beneficiaries, as the case may be, at the sole discretion of the Administrator, in either (A) uncertificated form, with the shares recorded in the name of Participant in the books and records of the
Company’s transfer agent; or (B) certificate form. 
 4.6 Rights as Stockholder. The holder of the Option shall
not be, nor have any of the rights or privileges of, a stockholder of the Company in respect of any shares of Stock purchasable upon the exercise of any part of the Option unless and until such shares of Stock shall have been issued by the Company
to such holder (as evidenced by the appropriate entry on the books of the Company or of a duly authorized transfer agent of the Company). No adjustment will be made for a dividend or other right for which the record date is prior to the date the
shares of Stock are issued, except as provided in Section 13(a) of the Plan. 

 ARTICLE V. 

OTHER PROVISIONS 

5.1 Administration. The Administrator shall have the power to interpret the Plan and this Agreement and to adopt such rules for
the administration, interpretation and application of the Plan as are consistent therewith and to interpret, amend or revoke any such rules. All actions taken and all interpretations and determinations made by the Administrator in good faith shall
be final and binding upon Participant, the Company and all other interested persons. No member of the Administrator shall be personally liable for any action, determination or interpretation made in good faith with respect to the Plan, this
Agreement or the Option. 
 5.2 Option Not Transferable. 

(a) The Option may not be sold, pledged, assigned or transferred in any manner other than by will or the laws of descent and
distribution, or, subject to the consent of the Administrator, pursuant to a DRO, unless and until the shares of Stock underlying the Option have been issued, and all restrictions applicable to such shares of Stock have lapsed. Neither the Option
nor any interest or right therein shall be liable for the debts, contracts or engagements of Participant or his or her successors in interest or shall be subject to disposition by transfer, alienation, anticipation, pledge, encumbrance, assignment
or any other means whether such disposition be voluntary or involuntary or by operation of law by judgment, levy, attachment, garnishment or any other legal or equitable proceedings (including bankruptcy), and any attempted disposition thereof shall
be null and void and of no effect, except to the extent that such disposition is permitted by the preceding sentence. 
 (b)
During the lifetime of Participant, only Participant may exercise the Option or any portion thereof, unless it has been disposed of with the consent of the Administrator pursuant to a DRO. After the death of Participant, any exercisable portion of
the Option may, prior to the time when the Option becomes unexercisable under Section 3.3 hereof, be exercised by Participant’s personal representative or by any person empowered to do so under the deceased Participant’s will or under
the then applicable laws of descent and distribution. 
 5.3 Adjustments. The Participant acknowledges that the Option is
subject to modification and termination in certain events as provided in this Agreement and Section 13 of the Plan. 
 5.4
Notices. Notices required or permitted hereunder shall be given in writing and shall be deemed effectively given when sent via email or upon personal delivery or upon deposit in the United States mail by certified mail, with postage and fees
prepaid, addressed to Participant to his or her address shown in the Company records, and to the Company at its principal executive office. By a notice given pursuant to this Section 5.4, either party may hereafter designate a different address
for notices to be given to that party. Any notice which is required to be given to Participant shall, if Participant is then deceased, be given to the person entitled to exercise his or her Option pursuant to Section 4.1 hereof by written
notice under this Section 5.4. 
 5.5 Titles. Titles are provided herein for convenience only and are not to serve
as a basis for interpretation or construction of this Agreement. 
 5.6 Governing Law. The laws of the State of Delaware
shall govern the interpretation, validity, administration, enforcement and performance of the terms of this Agreement regardless of the law that might be applied under principles of conflicts of laws. 

 5.7 Conformity to Securities Laws. The Participant acknowledges that the Plan and
this Agreement are intended to conform to the extent necessary with all provisions of the Securities Act and the Exchange Act and any and all regulations and rules promulgated by the Securities and Exchange Commission thereunder, and state
securities laws and regulations. Notwithstanding anything herein to the contrary, the Plan shall be administered, and the Option is granted and may be exercised, only in such a manner as to conform to such laws, rules and regulations. To the extent
permitted by applicable law, the Plan and this Agreement shall be deemed amended to the extent necessary to conform to such laws, rules and regulations. 

5.8 Amendments, Suspension and Termination. To the extent permitted by the Plan, this Agreement may be wholly or partially amended
or otherwise modified, suspended or terminated at any time or from time to time by the Administrator, provided, that, except as may otherwise be provided by the Plan, no amendment, modification, suspension or termination of this Agreement
shall adversely effect the Option in any material way without the prior written consent of the Participant. 
 5.9 Successors
and Assigns. The Company may assign any of its rights under this Agreement to single or multiple assignees, and this Agreement shall inure to the benefit of the successors and assigns of the Company. Subject to the restrictions on transfer
herein set forth in Section 5.2 hereof, this Agreement shall be binding upon Participant and his or her heirs, executors, administrators, successors and assigns. 

5.10 Notification of Disposition. If this Option is designated as an Incentive Stock Option, Participant shall give prompt notice
to the Company of any disposition or other transfer of any shares of Stock acquired under this Agreement if such disposition or transfer is made (a) within two years from the Grant Date with respect to such shares of Stock or (b) within
one year after the transfer of such shares of Stock to him. Such notice shall specify the date of such disposition or other transfer and the amount realized, in cash, other property, assumption of indebtedness or other consideration, by Participant
in such disposition or other transfer. 
 5.11 Limitations Applicable to Section 16 Persons. Notwithstanding any
other provision of the Plan or this Agreement, if Participant is subject to Section 16 of the Exchange Act, the Plan, the Option and this Agreement shall be subject to any additional limitations set forth in any applicable exemptive rule under
Section 16 of the Exchange Act (including any amendment to Rule 16b-3 of the Exchange Act) that are requirements for the application of such exemptive rule. To the extent permitted by applicable law, this Agreement shall be deemed amended to
the extent necessary to conform to such applicable exemptive rule 
 5.12 Not a Contract of Employment. Nothing in this
Agreement or in the Plan shall confer upon the Participant any right to continue to serve as an employee or other service provider of the Company or any of its Subsidiaries. 

5.13 Entire Agreement. The Plan, the Grant Notice and this Agreement (including all Exhibits thereto) constitute the entire
agreement of the parties and supersede in their entirety all prior undertakings and agreements of the Company and Participant with respect to the subject matter hereof.

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00176-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00176-of-00352.parquet"}]]